From Clinical to Non-clinical Outcomes in the Treatment of HIV: An Economic and Organizational Impact Assessment

Lucrezia Ferrario (), Barbara Menzaghi, Giuliano Rizzardini, Alessandro Roccia, Elisabetta Garagiola, Daniele Bellavia, Fabrizio Schettini and Emanuela Foglia
Additional contact information
Lucrezia Ferrario: LIUC-Università Cattaneo
Barbara Menzaghi: ASST Valle Olona Hospital
Giuliano Rizzardini: ASST Fatebenefratelli Sacco Hospital
Alessandro Roccia: Gilead Sciences SRL
Elisabetta Garagiola: LIUC-Università Cattaneo
Daniele Bellavia: LIUC-Università Cattaneo
Fabrizio Schettini: LIUC-Università Cattaneo
Emanuela Foglia: LIUC-Università Cattaneo

PharmacoEconomics - Open, 2025, vol. 9, issue 2, No 12, 313-326

Abstract: Abstract Objective The aim of this study was to define the economic and organizational impacts related to a broader utilization of bictegravir/emtricitabine/alafenamide (BIC/FTC/TAF) in Italian clinical practice. Methods A budget impact analysis—representing the evolution of the Italian National Healthcare Service (NHS) healthcare expenditure over 3 years—was developed, considering the overall Italian population treated for human immunodeficiency virus (HIV). Model input variables were treatment history, therapeutic regimen, development of adverse events, achievement of an undetectable viral load and total direct healthcare costs. Besides the BIA, an organizational impact assessment was conducted to determine the impact on the use of healthcare resources, assessing the release of organizational hospital assets, focusing on the management of drug-related adverse events. Data were collected from scientific evidence, Italian national and regional legislations and healthcare professionals’ reports. To verify the robustness of the economic and organizational impact assessment, sensitivity analyses were performed. Results Results demonstrate economic savings of about 26 million euros in total health spending, assuming a higher penetration rate for BIC/FTC/TAF. This change in the current case mix would lead to a reduction in the specific costs related to adverse event management (0.9 million euros; − 2.09%) and in the medical management of patients (38 million euros; − 7.79%), with a positive impact on the achievement of virological control. From an organizational perspective, a wider use of BIC/FTC/TAF generates a reduction in the utilization of healthcare resources due to a decrease in adverse events and complications. The model estimated a 19.64% reduction in HIV-related inpatient days, which freed up healthcare professional time. Conclusions Capable of improving both economic and organizational sustainability for the entire HIV care continuum, BIC/FTC/TAF is an efficient therapeutic strategy for people with HIV.

Date: 2025
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-024-00542-2 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:9:y:2025:i:2:d:10.1007_s41669-024-00542-2

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-024-00542-2

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().